Protalix BioTherapeutics (PLX) Total Current Liabilities (2010 - 2026)

Protalix BioTherapeutics' Total Current Liabilities history runs 17 years deep, the most recent figure standing at $27.4 million for Q1 2026.

• In Q1 2026, Total Current Liabilities rose 12.61% year-over-year to $27.4 million; the TTM figure through Mar 2026 stood at $27.4 million (up 12.61% YoY), while the FY2025 annual figure was $26.5 million, up 3.5% from the prior year.
• Total Current Liabilities was $27.4 million for Q1 2026 at Protalix BioTherapeutics, up from $26.5 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $58.0 million in Q2 2024 to a low of $21.9 million in Q3 2025.
• Historically, Total Current Liabilities has averaged $33.1 million across 5 years, with a median of $31.0 million in 2022.
• The sharpest annual moves came in 2022 and 2024: Total Current Liabilities sank 67.83% in 2022, then soared 150.86% in 2024.
• A 5-year view of Total Current Liabilities shows it stood at $32.4 million in 2022, then jumped by 40.4% to $45.5 million in 2023, then plunged by 43.73% to $25.6 million in 2024, then climbed by 3.5% to $26.5 million in 2025, then grew by 3.28% to $27.4 million in 2026.
• The last three Total Current Liabilities figures came in at $27.4 million (Q1 2026), $26.5 million (Q4 2025), and $21.9 million (Q3 2025), per Business Quant data.